Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 2
1977 2
1979 2
1981 3
1982 3
1983 2
1984 13
1985 11
1986 13
1987 18
1988 15
1989 12
1990 15
1991 23
1992 14
1993 7
1994 16
1995 18
1996 14
1997 30
1998 10
1999 16
2000 36
2001 18
2002 26
2003 28
2004 27
2005 25
2006 24
2007 27
2008 35
2009 37
2010 38
2011 37
2012 30
2013 38
2014 48
2015 39
2016 26
2017 35
2018 29
2019 15
2020 21
2021 13
2022 8
2023 9
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

885 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for lazzarin a
Search for Azzarin A instead (3 results)
Bictegravir.
Spagnuolo V, Castagna A, Lazzarin A. Spagnuolo V, et al. Among authors: lazzarin a. Curr Opin HIV AIDS. 2018 Jul;13(4):326-333. doi: 10.1097/COH.0000000000000468. Curr Opin HIV AIDS. 2018. PMID: 29746268 Review.
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina JM, Lazzarin A, Maggiolo F, Yazdanpanah Y, Andreatta K, Huang H, Hindman JT, Martin H, Pozniak A. Orkin C, et al. Among authors: lazzarin a. AIDS. 2024 Jun 1;38(7):983-991. doi: 10.1097/QAD.0000000000003865. Epub 2024 Feb 21. AIDS. 2024. PMID: 38349226 Free PMC article. Clinical Trial.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Among authors: lazzarin a. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
Biobanking for COVID-19 research.
Rovere-Querini P, Tresoldi C, Conte C, Ruggeri A, Ghezzi S, DE Lorenzo R, DI Filippo L, Farina N, Ramirez GA, Ripa M, Mancini N, Cantarelli E, Galli L, Poli A, DE Cobelli F, Bonini C, Manfredi AA, Franchini S, Spessot M, Carlucci M, Dagna L, Scarpellini P, Ambrosio A, DI Napoli D, Bosi E, Tresoldi M, Lazzarin A, Landoni G, Martino G, Zangrillo A, Poli G, Castagna A, Vicenzi E, Clementi M, Ciceri F; COVID-BioB Study Group. Rovere-Querini P, et al. Among authors: lazzarin a. Panminerva Med. 2022 Jun;64(2):244-252. doi: 10.23736/S0031-0808.20.04168-3. Epub 2020 Oct 19. Panminerva Med. 2022. PMID: 33073557
A Mobile Application for Exercise Intervention in People Living with HIV.
Bonato M, Turrini F, DE Zan V, Meloni A, Plebani M, Brambilla E, Giordani A, Vitobello C, Caccia R, Piacentini MF, LA Torre A, Lazzarin A, Merati G, Galli L, Cinque P. Bonato M, et al. Among authors: lazzarin a. Med Sci Sports Exerc. 2020 Feb;52(2):425-433. doi: 10.1249/MSS.0000000000002125. Med Sci Sports Exerc. 2020. PMID: 31415448 Clinical Trial.
Disseminated aspergillosis.
Lazzarin A, Capsoni F, Tortorano AM. Lazzarin A, et al. Am J Dis Child. 1982 Jul;136(7):654. doi: 10.1001/archpedi.1982.03970430086035. Am J Dis Child. 1982. PMID: 7091106 No abstract available.
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A. Ranzenigo M, et al. Among authors: lazzarin a. Drug Des Devel Ther. 2022 Jun 27;16:1975-1982. doi: 10.2147/DDDT.S358976. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35783200 Free PMC article.
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, Lazzarin A, Odeshoo L, Kelleher TD, Thiry A, Giordano MD, Schnittman SM. Cahn PE, et al. Among authors: lazzarin a. J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep;3(3):92-8. doi: 10.1177/154510970400300304. J Int Assoc Physicians AIDS Care (Chic). 2004. PMID: 15573713 Review.
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen.
Scutari R, Galli L, Alteri C, Poli A, Piermatteo L, Bigoloni A, Perno CF, Lazzarin A, Ceccherini-Silberstein F, Castagna A, Santoro MM, Gianotti N. Scutari R, et al. Among authors: lazzarin a. Int J Antimicrob Agents. 2023 May;61(5):106771. doi: 10.1016/j.ijantimicag.2023.106771. Epub 2023 Mar 3. Int J Antimicrob Agents. 2023. PMID: 36870403 Clinical Trial.
885 results